The Role of Markers of Inflammation in Traumatic Brain Injury
Top Cited Papers
Open Access
- 1 January 2013
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 4, 18
- https://doi.org/10.3389/fneur.2013.00018
Abstract
Within minutes of a traumatic impact, a robust inflammatory response is elicited in the injured brain. The complexity of this post-traumatic squeal involves a cellular component, comprising the activation of resident glial cells, microglia, and astrocytes, and the infiltration of blood leukocytes. The second component regards the secretion immune mediators, which can be divided into the following sub-groups: the archetypal pro-inflammatory cytokines (Interleukin-1, Tumor Necrosis Factor, Interleukin-6), the anti-inflammatory cytokines (IL-4, Interleukin-10, and TGF-beta), and the chemotactic cytokines or chemokines, which specifically drive the accumulation of parenchymal and peripheral immune cells in the injured brain region. Such mechanisms have been demonstrated in animal models, mostly in rodents, as well as in human brain. Whilst the humoral immune response is particularly pronounced in the acute phase following Traumatic brain injury (TBI), the activation of glial cells seems to be a rather prolonged effect lasting for several months. The complex interaction of cytokines and cell types installs a network of events, which subsequently intersect with adjacent pathological cascades including oxidative stress, excitotoxicity, or reparative events including angiogenesis, scarring, and neurogenesis. It is well accepted that neuroinflammation is responsible of beneficial and detrimental effects, contributing to secondary brain damage but also facilitating neurorepair. Although such mediators are clear markers of immune activation, to what extent cytokines can be defined as diagnostic factors reflecting brain injury or as predictors of long term outcome needs to be further substantiated. In clinical studies some groups reported a proportional cytokine production in either the cerebrospinal fluid or intraparenchymal tissue with initial brain damage, mortality, or poor outcome scores. However, the validity of cytokines as biomarkers is not broadly accepted. This review article will discuss the evidence from both clinical and laboratory studies exploring the validity of immune markers as a correlate to classification and outcome following TBI.Keywords
This publication has 153 references indexed in Scilit:
- The Cytokine Response to Human Traumatic Brain Injury: Temporal Profiles and Evidence for Cerebral Parenchymal ProductionJournal of Cerebral Blood Flow & Metabolism, 2010
- Role of Chemokines in CNS Health and Pathology: A Focus on the CCL2/CCR2 and CXCL8/CXCR2 NetworksJournal of Cerebral Blood Flow & Metabolism, 2009
- Roles of corticosterone in formalin-induced conditioned place aversion in ratsNeuroscience Letters, 2009
- Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatricsActa Neurochirurgica, 2009
- A systematic review finds methodological improvements necessary for prognostic models in determining traumatic brain injury outcomesJournal of Clinical Epidemiology, 2008
- IL-1β, IL-6 and TNF-α and outcomes of neonatal hypoxic ischemic encephalopathyBrain & Development, 2006
- Extracellular signal-regulated kinase-mediated IL-1-induced cortical neuron damage during traumatic brain injuryNeuroscience Letters, 2005
- Protein S-100b as serum marker for prediction of functional outcome in metastatic spinal cord compressionActa Neurochirurgica, 2004
- Identification of interleukin-6 (IL-6)-expressing neurons in the cerebellum and hippocampus of normal adult ratsNeuroscience Letters, 1994
- Penetration of interleukin-6 across the murine blood-brain barrierNeuroscience Letters, 1994